Skip to main content

Latest on the I-91 Viaduct

Interstate 91 patches 103112.jpg

Last year at about this time I wrote about the prospect of disruptive repairs to a stretch of the highway I-91 as it passes through Springfield, MA, just a short ways north of the border of the states of Massachusetts and Connecticut. This is a vital piece of infrastructure in my neck of the woods, so I'd like to keep readers of this blog up to date on it.

On June 25th, the Mass. Department of Transportation hosted a hearing on the project updating the community of those who drive there regularly, warning said community that preliminary construction work will begin any day now. J.F. White Contracting Co., of Framingham, won the bid and will serve as general contractor for the expected three year duration of the work.

The MassDOT is funding 20% of this work, the Federal Highway Administration will pick up the rest of the tab.

Finally, the project has become enmeshed over the last year with another timetable: that of casino construction. In the fullness of time, it has been decreed by the decreers of such matters, there will be an MGM Casino in downtown Springfield, so that Pioneer Valley gamblers won't have to undertake the long voyage to the coast of Long Island Sound and lose their wampum to Indian tribes gathered there. But the casino can hardly be expected to prove the engine of revitalization that MGM ensures us it can be unless people can get from the highway to their parking lots without too much aggravation and discomfort.

Comments

  1. Trying to find the Ultimate Dating Website? Create an account to find your perfect match.

    ReplyDelete

Post a Comment

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…